Report calls for more research into use of neuraminidase inhibitors such as Tamiflu in pandemics

9 October 2015

A report has called for more research into the use of neuraminidase inhibitors during an influenza pandemic, with particular interest in hospitalized patients and high-risk groups.

The report, published by the Academy of Medical Sciences and the Wellcome Trust and commissioned by the UK’s Department of Health, focused on Tamiflu (oseltamivir) from Roche (ROG: SIX) and GlaxoSmithKline’s (LSE: GSK) Relenza (zanamivir).

The report was mainly based on evidence from seasonal influenza outbreaks, and concluded that the neuraminidase inhibitors can lead to a reduction in duration of symptoms by between 14 and 17 hours. It also concluded that antivirals can significantly reduce deaths in hospitalized patients, especially in those who started treatment within 48 hours of symptoms beginning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK